Matches in Nanopublications for { ?s ?p "[Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- assertion description "[Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_assertion description "[Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247460.RA9_PMFF03FLWlt9WyovbAVOh-bJ6-y9bpmwnid6llqiY130_provenance.